

60/013,401, filed on March 14, 1996, and of Canadian Letters Patent No. 2,173,272,
filed on April 2, 1996.--

IN THE CLAIMS:

Please amend the claims as follows:

C2
~~103. (Amended) A method for [enhancing the stimulation of cells
production/release] stimulating the production of cells in the bone marrow and/or the
release of cells from the bone marrow and other tissue sites into the blood, the cells being
selected from at least one of the group consisting of hematopoietic cells and dendritic-
type cells, said method comprising administering to a patient an effective amount of a
form of hyaluronic acid selected from the group consisting of hyaluronic acid and
pharmaceutically acceptable salts thereof having a molecular weight of less than 750,000
daltons.~~

Subt
as D1
~~111. (Amended) A method for [the administration] administering to a human [of]
an effective amount of a form of hyaluronic acid comprising an effective amount of a
form of hyaluronic acid selected from the group consisting of hyaluronic acid and
pharmaceutically acceptable salts thereof having a molecular weight less than about
750,000 daltons for enhancing, stimulating and releasing hematopoietic cells and
dendritic-type cells from the bone marrow and other tissues into the blood.~~

C4
~~116. (Amended) A method of treating a patient [for enhancing the stimulation
of cells production/release] comprising stimulating the production of cells in the bone
marrow and/or the release of cells from the bone marrow and other tissues of cells
selected from at least one of the group consisting of hematopoietic cells and dendritic-
type cells, comprising administering a plurality of amounts of a form of hyaluronic acid
selected from the group consisting of hyaluronic acid and pharmaceutically acceptable
salts thereof having a molecular weight less than about 750,000 daltons to the patient at
predetermined intervals, at least one of such dosages being in an amount suitable to~~

C4
w/4
stimulate the ~~[production/release]~~ production and/or release of the cells from the bone marrow and other tissues into the blood.

124. (Amended) A method of treating a patient [for mobilizing] in order to mobilize hematopoietic cells from bone marrow and other tissues in a human into the blood of the human, the method comprising administering an effective amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than about 750,000 daltons to the patient.

C5
125. (Amended) A method of treating a patient [for mobilizing] in order to mobilize stem cells from bone marrow in a human into the circulation system of the human, the method comprising administering an effective amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof to the patient.

126. (Amended) A method of generating stem cells for transplantation comprising administering an effective amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than about 750,000 daltons to an individual and subsequently harvesting the cells to be transplanted from [the] peripheral blood.

C6
131. (Amended) [The] A method of [Claim 130 wherein the administration is to modulate] modulating symptoms of allergy or asthma comprising administering an effective amount of a form of hyaluronic acid selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than about 750,000 daltons for enhancing, stimulating, and releasing mast cell progenitors and dendritic-type cells from the bone marrow and other tissues into the blood.